亚洲人群直接口服抗凝药复杂上消化道出血风险分析
基于香港2011至2020年58,229例新暴露于四种DOAC的回顾性队列,采用IPTW平衡基线,随访2年并以非UGIB死亡为竞争风险。与阿哌沙班相比,艾多沙班和利伐沙班与复杂UGIB风险显著升高相关,达比加群无显著差异。
要点
- 艾多沙班和利伐沙班较阿哌沙班复杂UGIB风险更高,达比加群无显著差异。
- 艾多沙班致害需治疗人数244,利伐沙班为427(基于原文SHR与置信区间计算)。
- 高龄≥80岁或eGFR<60 mL/min/1.73 m2者,阿哌沙班出血风险更低。
核心结论
- 在无既往抗凝暴露的中国人群中,阿哌沙班使用者2年复杂UGIB风险低于艾多沙班和利伐沙班使用者,但与达比加群使用者无显著差异。
研究设计与样本
- 行业独立、基于人群的回顾性队列研究,纳入香港2011至2020年新暴露于阿哌沙班、达比加群、艾多沙班或利伐沙班的受试者共58,229例。
- 采用逆概率治疗加权平衡DOAC组间基线人口学、合并症、药物及实验室结果,随访2年,非UGIB死亡作为竞争风险,Fine-Gray模型生成亚分布风险比,Benjamini-Hochberg法控制FDR。
主要发现
- 致害需治疗人数:艾多沙班244,利伐沙班427。
- 亚组分析中,年龄≥80岁或eGFR<60 mL/min/1.73 m2者,阿哌沙班与更低出血风险相关;低剂量阿哌沙班在所有低剂量DOAC中出血风险更低。
关键数值与推荐
- 主要结局复杂UGIB定义:任何UGIB相关死亡,或UGIB伴血红蛋白下降>2 g/dL、输血、急诊内镜操作、放射/外科干预或30天内再出血。
临床怎么用
- 在无既往抗凝暴露的亚洲人群中,选择DOAC时可考虑阿哌沙班以降低复杂UGIB风险,尤其高龄或肾功能不全者。
- 使用艾多沙班或利伐沙班时需更关注上消化道出血风险,低剂量阿哌沙班可能出血风险更低。
局限性
- 回顾性观察性设计可能存在残余混杂。
- 仅纳入香港中国人群,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Asian data on complicated upper gastrointestinal bleeding (UGIB) risks among direct oral anticoagulants (DOACs) are limited. METHODS: An industry-independent, population-based, retrospective cohort study was performed in Hong Kong during 2011 to 2020. Subjects with new exposure to apixaban, dabigatran, edoxaban, or rivaroxaban were included. Baseline demographics, comorbidities, drugs, and laboratory results were balanced between DOACs by inverse probability of treatment weighting. Subjects were followed for 2 years with non-UGIB deaths considered as competing risks. Subdistribution hazard ratios (SHRs) were generated by Fine-Gray model. False discovery rate (FDR) was controlled by the Benjamini-Hochberg procedure for multiplicity. The primary outcome was complicated UGIB, defined as any UGIB-related death, or UGIB with a hemoglobin drop >2 g/dL; blood transfusion; emergent endoscopic procedure; radiological/surgical intervention; or rebleeding within 30 days. RESULTS: A total of 58,229 subjects with new DOACs exposure were included (22,359 apixaban, 20,639 dabigatran, 2068 edoxaban, and 13,163 rivaroxaban). Compared with apixaban, edoxaban (SHR, 1.891; 95% confidence interval [CI], 1.091-3.275; P = .025; FDR-adjusted P = .039) and rivaroxaban (SHR, 1.441; 95% CI, 1.047-1.983; P = .026; FDR-adjusted P = .039), but not dabigatran, were associated with significantly higher risks of complicated UGIB, with a number-needed-to-harm of 244 for edoxaban and 427 for rivaroxaban, respectively. In subgroup analysis, apixaban was associated with a lower bleeding risk in subjects with age ≥80 years or estimated glomerular filtrate rate <60 mL/min/1.73 m2. Low-dose apixaban was associated with a lower bleeding risk among all low-dose DOACs. CONCLUSIONS: This Chinese population-based observational study demonstrated a lower 2-year risk of complicated UGIB in apixaban users compared with edoxaban and rivaroxaban, but not dabigatran, users among subjects without prior anticoagulant exposure.
引用
- Lau LHS, Xiao X, Yip TCF, et al. Risk of Complicated Upper Gastrointestinal Bleeding With Direct Oral Anticoagulants: An Asian Population-Based Analysis. Clin Gastroenterol Hepatol. 2026. PMID: 42055303. doi:10.1016/j.cgh.2026.04.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。